209 related articles for article (PubMed ID: 12168905)
1. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
2. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
3. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
4. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
9. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
11. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer].
Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108
[TBL] [Abstract][Full Text] [Related]
12. [The changes in serum neuron-specific enolase in patients with small cell lung cancer].
Taitou H; Sakurai M; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ookura H; Saijo N
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3046-9. PubMed ID: 2823722
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
14. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
[TBL] [Abstract][Full Text] [Related]
15. [Serum NSE (neuron-specific enolase) levels in small cell lung cancer, with special reference to the measurement of serial serum NSE levels].
Kawachi S; Shimabukuro Z; Aoyama A; Yano T; Hasegawa K; Tsuboi E; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2469-74. PubMed ID: 3039919
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical implication of neuron-specific enolase and creatine kinase BB in small cell lung cancer.
Ariyoshi Y; Kato K; Ueda R; Takahashi T; Sato T; Akatsuka H; Kuwabara M; Kito K; Suchi T; Nishimura M
Jpn J Clin Oncol; 1986 Sep; 16(3):213-21. PubMed ID: 3022031
[TBL] [Abstract][Full Text] [Related]
17. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
18. [The "neuron-specific enolase" tumor marker as a prognostic indicator in small cell bronchial carcinoma].
Hoster M; Kirchheiner T; Rühle KH
Pneumologie; 1995 Aug; 49(8):470-4. PubMed ID: 7479642
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
20. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
Boher JM; Pujol JL; Grenier J; Daurès JP
Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
